Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Open Lending Corporation regarding a class action lawsuit due to alleged misleading statements and omissions related to the company's financial performance and risk-based pricing models [1][2]. Summary by Relevant Sections Allegations - Defendants allegedly made false statements and concealed information regarding: - Misrepresentation of the capabilities of the company's risk-based pricing models - Materially misleading statements about the company's profit share revenue - Failure to disclose that the 2021 and 2022 vintage loans were worth significantly less than their outstanding loan balances - Misrepresentation of the underperformance of the 2023 and 2024 vintage loans [1]. Class Period and Registration - The class period for the lawsuit is from February 24, 2022, to March 31, 2025 - Shareholders who purchased shares during this period are encouraged to register for the class action by June 30, 2025, to potentially be appointed as lead plaintiffs [1][2]. Next Steps for Shareholders - Registered shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle - Participation in the case incurs no cost or obligation for shareholders [2]. Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit, fraud, and illegal business practices - The firm is committed to ensuring companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Cerevel Therapeutics Holdings, Inc. regarding a class action lawsuit related to alleged misleading statements and omissions during a secondary stock offering, which may have artificially deflated the stock price prior to a merger announcement with AbbVie Inc. [1][2] Group 1: Allegations and Impact - Cerevel's October 16, 2023 secondary stock offering documents allegedly omitted material facts about AbbVie's interest in acquiring Cerevel at a significantly higher price than the offering price of $22.81 per share, leading to an artificial deflation of Cerevel's stock price [2] - Bain Capital, Cerevel's controlling shareholder, reportedly acquired shares at this artificially depressed price while possessing nonpublic information about AbbVie's acquisition interest, resulting in a windfall of over $120 million when AbbVie agreed to acquire Cerevel for $45 per share on December 6, 2023 [2] - The January 18, 2024 Proxy statement from Cerevel is claimed to have misled investors regarding the nature and timing of AbbVie's interest in the company [2] Group 2: Class Action Details - The class period for the lawsuit includes shareholders who sold or disposed of Cerevel stock from October 11, 2023, to August 1, 2024, and those who held shares as of January 8, 2024, entitled to vote on the merger [1] - The deadline for shareholders to register for the class action and seek lead plaintiff status is June 3, 2025, with no cost or obligation to participate [3] - Registered shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's status [3]

LOS ANGELES, May 20, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cleveland-Cliffs Inc. ("Cleveland-Cliffs" or "the Company") (NYSE: CLF) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Cleveland-Cliffs reportd its financial results for Q1 2025 on May 7, 20 ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Sana Biotechnology, Inc. regarding a class action lawsuit due to allegations of materially false and misleading statements made by the company during a specified class period [1][2]. Group 1: Allegations Against Sana Biotechnology - The complaint alleges that during the class period from March 17, 2023, to November 4, 2024, Sana was at significant risk of having insufficient funds to maintain its operations and advance its product candidates [1]. - It is claimed that product candidates SC291 in oncology, SC379, and SG299 were less promising than what the defendants had communicated to investors [1]. - To preserve cash and focus on more promising candidates, Sana was likely to decrease funding for or discontinue SC291, SC379, and SG299, as well as significantly reduce its workforce [1]. - The defendants allegedly overstated Sana's financial capacity to maintain operations and advance existing product candidates, leading to materially false and misleading public statements [1]. Group 2: Class Action Participation - Shareholders who purchased shares of SANA during the class period are encouraged to register for the class action, with a deadline of May 20, 2025, to seek lead plaintiff status [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [2]. - Participation in the case incurs no cost or obligation for the shareholders [2]. Group 3: About The Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit, fraud, and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions that inflated stock prices [3].

NEW YORK, May 12, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of West Pharmaceutical Services, Inc. (NYSE: WST).Shareholders who purchased shares of WST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/west-pharmaceutical-services-inc-loss-submission-form/?id=147732&from=4 CLA ...

NEW YORK, May 12, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Actinium Pharmaceuticals, Inc. (NYSE: ATNM).Shareholders who purchased shares of ATNM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/actinium-loss-submission-form/?id=147716&from=4CLASS PERIOD: October 31, 2022 ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Sana Biotechnology, Inc. regarding a class action lawsuit due to allegations of misleading statements and financial misrepresentation during a specified class period [1][2]. Group 1: Allegations - The complaint alleges that during the class period from March 17, 2023, to November 4, 2024, Sana Biotechnology was at significant risk of having insufficient funds to maintain its operations and advance its product candidates [1]. - It is claimed that product candidates SC291 in oncology, SC379, and SG299 were less promising than what the defendants had communicated to investors [1]. - The company is likely to decrease funding for or discontinue certain product candidates and significantly reduce its workforce to preserve cash for more promising projects [1]. - The defendants allegedly overstated Sana's financial capacity to maintain operations and advance existing product candidates, leading to materially false and misleading public statements [1]. Group 2: Next Steps for Shareholders - Shareholders who purchased shares of SANA during the specified timeframe are encouraged to register for the class action, with a deadline of May 20, 2025, to seek lead plaintiff status [2]. - Registered shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the lifecycle of the case [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit, fraud, and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements or omissions that led to artificial inflation of stock prices [3].

Core Viewpoint - Civitas Resources, Inc. is facing allegations of misleading shareholders regarding its oil production capabilities and financial health, particularly in light of expected production declines in 2025 [1][2]. Allegations Summary - Civitas is likely to significantly reduce its oil production in 2025 due to declines following a production peak at the DJ Basin in Q4 2024 and a low TIL count at the end of 2024 [1]. - Increasing oil production would necessitate acquiring additional acreage and development locations, leading to significant debt and potential asset sales to cover acquisition costs [1]. - The company's financial condition may force it to implement disruptive cost reduction measures, including substantial workforce reductions [1]. - As a result, Civitas's business and financial prospects, as well as its operational capabilities, were likely overstated [1]. - The public statements made by Civitas were materially false and misleading throughout the relevant period [1]. Class Action Details - The class period for the allegations spans from February 27, 2024, to February 24, 2025 [1]. - Shareholders are encouraged to register for the class action by July 1, 2025, to participate in potential recovery [2]. - Registered shareholders will receive updates through a portfolio monitoring software during the case lifecycle [2].

NEW YORK, May 8, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Canopy Growth Corporation (NASDAQ: CGC).Shareholders who purchased shares of CGC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/canopy-growth-corporation-loss-submission-form-2/?id=147312&from=4CLASS PERIOD: May ...

Investigation Overview - Berman Tabacco is investigating potential securities law violations by Compass Diversified Holdings (NASDAQ:CODI) [1] - Compass has initiated an internal investigation into the financing, accounting, and inventory practices of its subsidiary, Lugano Holding, Inc. [2] - The investigation was prompted by concerns reported to management regarding Lugano's practices [2] Internal Investigation Details - The Audit Committee of Compass retained outside legal counsel to assist in the ongoing investigation [2] - The focus of the investigation includes unrecorded financing arrangements and irregularities in sales, cost of sales, inventory, and accounts receivable at Lugano [2] - Due to preliminary findings, the Audit Committee concluded that the consolidated financial statements for the fiscal year ended December 31, 2024, should no longer be relied upon [2] Management Changes - Mordechai Haim 'Moti' Ferder resigned as CEO of Lugano and from all related positions on May 7, 2025, in connection with the investigation [2] - Following the announcement of the investigation, shares of Compass experienced a decline in after-hours trading [2]